4.14MMarket Cap-135P/E (TTM)
2.8000High2.5500Low325.37KVolume2.7900Open2.7100Pre Close857.76KTurnover20.97%Turnover RatioLossP/E (Static)1.61MShares27.000052wk High1.18P/B3.99MFloat Cap2.550052wk Low--Dividend TTM1.55MShs Float3341518.3292Historical High--Div YieldTTM9.23%Amplitude2.5500Historical Low2.6360Avg Price1Lot Size
Windtree Therapeutics Stock Forum
has a nice catalyst next week the 30th lots of shorts matter a time before this rips buy now great place to add under $3
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Windtree Therapeutics (NasdaqCM: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock.
The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo.
Significant benefits were also observed in many secondar...
Windtree Therapeutics Inc: Istaroxime Significantly Improved Primary Endpoint of Systolic Blood Pressure Profile Over Six Hours
📊⚡️📊
No comment yet